List view / Grid view
In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.
As ISO IDMP data standards gradually progress to implementation in Europe, Lise Stevens asks what bearing they might have had in the context of the global COVID-19 crisis.
Dr Ash Ramzan, founder and principal consultant at Woodley BioReg, discusses how the COVID-19 pandemic has forced regulatory processes to adapt, focusing on the regulatory flexibilities introduced by the UK’s MHRA.
The pharmaceutical cold chain includes numerous participants – David Lewandowski discusses why this must be scalable to ensure efficient delivery of a COVID-19 vaccine.
European Pharmaceutical Review spoke with Dean Petkanas from Neuropathix, formerly known as Kannalife, to find out why a CBD-inspired molecule can offer an improved therapeutic value.
In this Q&A, Nick Pike, Chief Revenue Officer at Vizibl, outlines with EPR’s Hannah Balfour the benefits of Software as a Service (SaaS) for pharmaceutical companies and describes how its adoption can enable companies to achieve many goals faster; from collaborating on bringing new products to market to reaching their…
The top considerations for hand sanitiser manufacturers in the UK are outlined in this article by Robert Bussey.
Mary Alice Dwyer and Sameer Lal explain how pharmaceutical companies can embrace a more customer-centric approach through digital transformation.
This article explores how COVID-19 has impacted clinical investigation sites and what companies could do to mitigate the effect on trials moving forwards.
G Balaji and Ravi Kalla explains how Pharma 4.0 can be implemented at a CRO to enable work to continue even during a global pandemic.
Aubrey Dan explains how EmpowerPharm developed its synthetic CBD tablet and why a novel formulation could help combat a range of indications.
Phoebe Chubb explains how emerging technologies are enabling laboratory automation to occur on a smaller scale, with a less prohibitive price tag, and discusses the potential of smart labs to significantly transform the R&D environment.
EPR’s Hannah Balfour explores pharma’s reputation prior to the pandemic and the impact of COVID-19, highlighting areas which pharma could focus on to improve consumer relations and drive public engagement and trust.
This article explores a novel method for fungal identification. A case study is presented which showed this method was superior to the reference method with increased identification rates and lower misidentification.
In this article, William E Weiser discusses the advantages global pharmaceutical developers and manufacturers can gain from a laboratory information management system (LIMS) solution and highlights the key considerations to be made when integrating and standardising LIMS in their organisations.
